panitumumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
human origin 4955 339177-26-3

Description:

MoleculeDescription

Synonyms:

  • panitumumab
  • vectibix
  • ABX-EGF
Recombinant human monoclonal antibody that binds to and inhibits the function of the EPIDERMAL GROWTH FACTOR RECEPTOR. It is used in the treatment of EGFR-expressing metastatic colorectal cancer that expresses wild-type ras gene (see GENES, RAS).
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 2007 EMA Amgen Europe B.V.
Sept. 27, 2006 FDA AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 1494.17 26.80 308 12519 6046 90609574
Skin toxicity 984.00 26.80 221 12606 6558 90609062
Paronychia 649.07 26.80 163 12664 7843 90607777
Hypomagnesaemia 580.05 26.80 210 12617 35378 90580242
Neutropenia 347.80 26.80 273 12554 224631 90390989
Dry skin 335.81 26.80 188 12639 87885 90527735
Neuropathy peripheral 328.05 26.80 217 12610 136753 90478867
Therapy partial responder 321.62 26.80 120 12707 21923 90593697
Rash pustular 282.96 26.80 85 12742 7964 90607656
Rash 265.29 26.80 432 12395 795668 89819952
Skin fissures 248.77 26.80 98 12729 20711 90594909
Diarrhoea 239.42 26.80 453 12374 938737 89676883
Disease progression 239.32 26.80 189 12638 156426 90459194
Metastases to liver 218.02 26.80 98 12729 28709 90586911
Polyneuropathy 179.55 26.80 76 12751 19265 90596355
Skin disorder 169.31 26.80 89 12738 36617 90579003
Stomatitis 154.43 26.80 192 12635 274506 90341114
Neurotoxicity 140.36 26.80 66 12761 21401 90594219
Thrombocytopenia 123.84 26.80 150 12677 208575 90407045
Peripheral sensory neuropathy 122.69 26.80 47 12780 9203 90606417
Palmar-plantar erythrodysaesthesia syndrome 120.89 26.80 65 12762 27958 90587662
Mucosal inflammation 106.47 26.80 78 12749 57547 90558073
Xeroderma 105.75 26.80 21 12806 335 90615285
Xerosis 99.05 26.80 26 12801 1485 90614135
Trichomegaly 97.16 26.80 16 12811 80 90615540
Skin reaction 97.10 26.80 49 12778 18504 90597116
Hypocalcaemia 96.04 26.80 65 12762 42303 90573317
Neutrophil count decreased 91.56 26.80 78 12749 71454 90544166
Blood magnesium decreased 89.68 26.80 44 12783 15649 90599971
Carcinoembryonic antigen increased 87.69 26.80 26 12801 2324 90613296
Acne 87.62 26.80 53 12774 28454 90587166
Colorectal cancer metastatic 87.57 26.80 21 12806 828 90614792
Anaemia 85.09 26.80 167 12660 352635 90262985
Erythema 84.65 26.80 131 12696 229115 90386505
Hypokalaemia 82.22 26.80 97 12730 131019 90484601
Conjunctivitis 80.41 26.80 49 12778 26657 90588963
Drug ineffective 73.13 26.80 54 12773 1384244 89231376
Leukopenia 70.70 26.80 79 12748 100631 90514989
Growth of eyelashes 70.70 26.80 14 12813 220 90615400
Malignant neoplasm progression 65.23 26.80 78 12749 106792 90508828
Hypertrichosis 62.40 26.80 18 12809 1461 90614159
Metastases to ovary 59.37 26.80 14 12813 513 90615107
Dehydration 59.36 26.80 102 12725 194345 90421275
Death 58.52 26.80 169 12658 456382 90159238
Metastases to lung 57.73 26.80 33 12794 15958 90599662
Arthralgia 56.38 26.80 20 12807 778502 89837118
Febrile neutropenia 56.32 26.80 89 12738 158260 90457360
Dermatitis 52.52 26.80 35 12792 22185 90593435
Abdominal discomfort 52.41 26.80 4 12823 477324 90138296
Intravascular haemolysis 51.20 26.80 12 12815 428 90615192
Skin lesion 50.37 26.80 42 12785 37323 90578297
Headache 48.94 26.80 31 12796 862715 89752905
Decreased appetite 47.84 26.80 139 12688 376401 90239219
Nasopharyngitis 45.87 26.80 3 12824 407101 90208519
Ileal perforation 43.99 26.80 11 12816 517 90615103
Ileus 43.84 26.80 28 12799 16518 90599102
Pulmonary embolism 43.05 26.80 71 12756 130749 90484871
Interstitial lung disease 42.13 26.80 53 12774 76352 90539268
Rash maculo-papular 41.20 26.80 39 12788 40894 90574726
Haematotoxicity 40.31 26.80 24 12803 12511 90603109
Gastrointestinal toxicity 38.15 26.80 21 12806 9446 90606174
Depilation 37.53 26.80 6 12821 24 90615596
Fall 37.25 26.80 11 12816 481799 90133821
Peritoneal disorder 37.06 26.80 10 12817 635 90614985
Peripheral swelling 36.71 26.80 7 12820 413099 90202521
Xerophthalmia 36.48 26.80 10 12817 674 90614946
Pemphigus 35.13 26.80 3 12824 326861 90288759
Hepatic enzyme increased 34.52 26.80 5 12822 360731 90254889
Thrombocytopenic purpura 34.10 26.80 12 12815 1849 90613771
Intestinal obstruction 32.92 26.80 33 12794 37098 90578522
Hypoalbuminaemia 32.73 26.80 23 12804 15874 90599746
Ascites 32.71 26.80 37 12790 47703 90567917
Hepatectomy 32.70 26.80 7 12820 164 90615456
Scab 32.27 26.80 19 12808 9702 90605918
Swelling 31.60 26.80 10 12817 419048 90196572
Metastases to lymph nodes 31.51 26.80 20 12807 11669 90603951
Keratitis 31.47 26.80 14 12813 3992 90611628
Wound 29.45 26.80 4 12823 302976 90312644
Metastasis 28.61 26.80 15 12812 6122 90609498
Drug intolerance 28.31 26.80 14 12813 447577 90168043
Pain of skin 27.95 26.80 21 12806 16061 90599559
Large intestine perforation 27.14 26.80 17 12810 9695 90605925

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 2307.84 24.18 572 20350 7167 42593246
Skin toxicity 1624.06 24.18 418 20504 6131 42594282
Paronychia 1234.35 24.18 308 20614 3947 42596466
Hypomagnesaemia 996.23 24.18 411 20511 28077 42572336
Rash 650.03 24.18 735 20187 276219 42324194
Rash pustular 557.76 24.18 180 20742 6035 42594378
Metastases to liver 439.46 24.18 196 20726 16130 42584283
Therapy partial responder 434.59 24.18 207 20715 19814 42580599
Neuropathy peripheral 389.14 24.18 353 20569 101500 42498913
Stomatitis 366.21 24.18 255 20667 50074 42550339
Skin reaction 355.85 24.18 133 20789 6934 42593479
Interstitial lung disease 347.74 24.18 296 20626 78166 42522247
Skin disorder 313.10 24.18 157 20765 16787 42583626
Neutropenia 290.59 24.18 419 20503 199012 42401401
Diarrhoea 270.95 24.18 654 20268 460195 42140218
Dry skin 244.41 24.18 197 20725 48141 42552272
Polyneuropathy 237.74 24.18 135 20787 18526 42581887
Disease progression 236.00 24.18 320 20602 143336 42457077
Acne 227.53 24.18 118 20804 13526 42586887
Conjunctivitis 210.31 24.18 110 20812 12829 42587584
Folliculitis 203.34 24.18 83 20839 5475 42594938
Metastases to lung 182.46 24.18 96 20826 11328 42589085
Skin fissures 156.48 24.18 82 20840 9594 42590819
Palmar-plantar erythrodysaesthesia syndrome 141.83 24.18 101 20821 20481 42579932
Carcinoembryonic antigen increased 140.80 24.18 40 20882 858 42599555
Mucosal inflammation 133.62 24.18 142 20780 49232 42551181
Colorectal cancer metastatic 129.28 24.18 38 20884 923 42599490
Drug ineffective 123.80 24.18 79 20843 630118 41970295
Peripheral sensory neuropathy 110.49 24.18 63 20859 8699 42591714
Blood magnesium decreased 106.79 24.18 59 20863 7667 42592746
Neurotoxicity 106.07 24.18 90 20832 23561 42576852
Thrombocytopenia 102.32 24.18 262 20660 190017 42410396
Decreased appetite 99.80 24.18 262 20660 192875 42407538
Hypocalcaemia 92.82 24.18 93 20829 30080 42570333
Xerosis 92.30 24.18 29 20893 887 42599526
Drug interaction 83.87 24.18 15 20907 266984 42333429
Skin lesion 80.37 24.18 82 20840 27092 42573321
Growth of eyelashes 77.46 24.18 16 20906 79 42600334
Trichomegaly 76.04 24.18 14 20908 32 42600381
Neutrophil count decreased 75.96 24.18 122 20800 63293 42537120
Metastases to peritoneum 74.24 24.18 32 20890 2417 42597996
Headache 73.98 24.18 14 20908 239355 42361058
Erythema 73.70 24.18 164 20758 108629 42491784
Metastases to lymph nodes 69.96 24.18 41 20881 5957 42594456
Arthralgia 67.85 24.18 10 20912 205228 42395185
Dermatitis 65.49 24.18 51 20871 11824 42588589
Product use in unapproved indication 52.46 24.18 13 20909 184443 42415970
Ileus 51.64 24.18 55 20867 19084 42581329
Hepatectomy 50.91 24.18 12 20910 118 42600295
Fall 50.63 24.18 26 20896 234494 42365919
Haematotoxicity 49.64 24.18 42 20880 10943 42589470
Mucosal toxicity 49.46 24.18 14 20908 296 42600117
Hypertrichosis 48.27 24.18 16 20906 582 42599831
Rash maculo-papular 47.43 24.18 74 20848 37429 42562984
Xeroderma 46.20 24.18 12 20910 181 42600232
Gastrointestinal toxicity 45.88 24.18 27 20895 3952 42596461
Metastases to pelvis 45.00 24.18 14 20908 414 42599999
Colorectal cancer recurrent 44.95 24.18 10 20912 74 42600339
Eyelash changes 42.67 24.18 8 20914 21 42600392
Somnolence 40.00 24.18 10 20912 141095 42459318
Product dose omission issue 39.95 24.18 13 20909 154352 42446061
Mucocutaneous rash 39.16 24.18 8 20914 37 42600376
Hypersensitivity 39.12 24.18 100 20822 72270 42528143
Blepharitis 38.90 24.18 19 20903 1914 42598499
Hepatic lesion 37.91 24.18 25 20897 4469 42595944
Overdose 37.49 24.18 4 20918 105260 42495153
Carbohydrate antigen 19-9 increased 37.39 24.18 11 20911 268 42600145
Gene mutation 37.33 24.18 18 20904 1763 42598650
Pulmonary embolism 37.09 24.18 136 20786 119476 42480937
Dizziness 36.69 24.18 41 20881 249213 42351200
Acne pustular 36.32 24.18 9 20913 111 42600302
Nail disorder 35.57 24.18 19 20903 2308 42598105
Cough 35.18 24.18 22 20900 178081 42422332
Intestinal obstruction 34.91 24.18 54 20868 27104 42573309
Perioral dermatitis 34.70 24.18 10 20912 226 42600187
Pustule 34.41 24.18 15 20907 1164 42599249
Diaphragmatic operation 34.33 24.18 7 20915 32 42600381
Dehydration 34.18 24.18 149 20773 141618 42458795
Enterocolitis 33.11 24.18 32 20890 9897 42590516
Hypokalaemia 32.62 24.18 93 20829 71628 42528785
Ectropion 32.56 24.18 9 20913 174 42600239
Transient aphasia 32.23 24.18 12 20910 617 42599796
Myalgia 30.99 24.18 5 20917 96075 42504338
Skin exfoliation 30.78 24.18 65 20857 41488 42558925
Condition aggravated 30.21 24.18 51 20871 260703 42339710
Pain 29.19 24.18 47 20875 244801 42355612
Pain in extremity 29.19 24.18 19 20903 150585 42449828
Tumour marker increased 28.81 24.18 12 20910 832 42599581
Insomnia 28.80 24.18 11 20911 118242 42482171
Cardiac failure congestive 28.65 24.18 4 20918 85598 42514815
Catheter site thrombosis 28.64 24.18 8 20914 161 42600252
Device related infection 28.44 24.18 42 20880 20237 42580176
Toxicity to various agents 28.25 24.18 43 20879 229093 42371320
Weight increased 28.09 24.18 9 20913 107974 42492439
Epidermal naevus syndrome 27.96 24.18 5 20917 9 42600404
Livedo reticularis 27.34 24.18 17 20905 2747 42597666
Pulmonary toxicity 27.19 24.18 27 20895 8628 42591785
Neoplasm progression 27.08 24.18 50 20872 28950 42571463
Dermatitis infected 26.77 24.18 8 20914 206 42600207
Colon cancer metastatic 26.23 24.18 14 20908 1698 42598715
Anaphylactoid reaction 26.15 24.18 17 20905 2966 42597447
Asthenia 25.80 24.18 230 20692 280563 42319850
Anxiety 25.76 24.18 13 20909 118547 42481866
Cholangitis 25.76 24.18 29 20893 10698 42589715
Astringent therapy 25.48 24.18 5 20917 18 42600395
Rash papular 25.12 24.18 30 20892 11781 42588632
Urinoma 25.00 24.18 8 20914 260 42600153
Proctectomy 24.73 24.18 7 20915 148 42600265
Intestinal transit time abnormal 24.68 24.18 5 20917 22 42600391
Traumatic ulcer 24.50 24.18 5 20917 23 42600390

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 3581.96 24.49 800 28852 11895 110547752
Skin toxicity 2394.70 24.49 569 29083 11214 110548433
Paronychia 1625.83 24.49 412 29240 10669 110548978
Hypomagnesaemia 1371.30 24.49 539 29113 59831 110499816
Therapy partial responder 827.08 24.49 327 29325 36734 110522913
Neuropathy peripheral 808.67 24.49 536 29116 178741 110380906
Rash pustular 791.76 24.49 242 29410 12587 110547060
Metastases to liver 702.31 24.49 287 29365 35099 110524548
Neutropenia 598.85 24.49 612 29040 374008 110185639
Rash 579.75 24.49 889 28763 820075 109739572
Dry skin 521.64 24.49 337 29315 107316 110452331
Disease progression 503.21 24.49 459 29193 243575 110316072
Polyneuropathy 473.91 24.49 211 29441 31801 110527846
Interstitial lung disease 438.70 24.49 335 29317 138999 110420648
Diarrhoea 435.73 24.49 946 28706 1138559 109421088
Skin disorder 426.67 24.49 215 29437 42698 110516949
Stomatitis 383.73 24.49 415 29237 269827 110289820
Skin fissures 351.69 24.49 158 29494 24300 110535347
Acne 292.87 24.49 154 29498 33366 110526281
Skin reaction 292.60 24.49 133 29519 21011 110538636
Palmar-plantar erythrodysaesthesia syndrome 274.39 24.49 158 29494 40867 110518780
Thrombocytopenia 261.84 24.49 390 29262 348495 110211152
Conjunctivitis 258.13 24.49 142 29510 33650 110525997
Metastases to lung 251.22 24.49 123 29529 22940 110536707
Neurotoxicity 236.43 24.49 145 29507 42062 110517585
Mucosal inflammation 219.78 24.49 192 29460 95949 110463698
Carcinoembryonic antigen increased 207.55 24.49 61 29591 2763 110556884
Peripheral sensory neuropathy 199.93 24.49 95 29557 16585 110543062
Colorectal cancer metastatic 188.73 24.49 50 29602 1539 110558108
Neutrophil count decreased 163.03 24.49 181 29471 120760 110438887
Hypocalcaemia 160.42 24.49 136 29516 65230 110494417
Trichomegaly 155.52 24.49 28 29624 121 110559526
Xeroderma 152.26 24.49 35 29617 588 110559059
Skin lesion 144.61 24.49 116 29536 51515 110508132
Decreased appetite 130.61 24.49 349 29303 475497 110084150
Headache 129.77 24.49 38 29614 882339 109677308
Arthralgia 129.41 24.49 26 29626 779606 109780041
Xerosis 122.85 24.49 36 29616 1613 110558034
Drug ineffective 122.54 24.49 137 29515 1520403 109039244
Erythema 115.88 24.49 247 29405 291200 110268447
Dermatitis 112.59 24.49 78 29574 27759 110531888
Growth of eyelashes 104.75 24.49 21 29631 176 110559471
Blood magnesium decreased 102.61 24.49 65 29587 19931 110539716
Hypertrichosis 98.91 24.49 31 29621 1747 110557900
Metastases to lymph nodes 95.44 24.49 56 29596 14976 110544671
Hepatectomy 93.45 24.49 21 29631 317 110559330
Leukopenia 92.77 24.49 153 29499 148638 110411009
Metastases to peritoneum 92.75 24.49 40 29612 5570 110554077
Haematotoxicity 89.81 24.49 61 29591 21021 110538626
Pain 82.35 24.49 81 29571 954874 109604773
Hypokalaemia 82.32 24.49 163 29489 182285 110377362
Drug interaction 82.23 24.49 17 29635 500166 110059481
Ileus 81.72 24.49 67 29585 30662 110528985
Fall 79.87 24.49 31 29621 603451 109956196
Nasopharyngitis 74.72 24.49 9 29643 394352 110165295
Peripheral swelling 74.67 24.49 10 29642 404024 110155623
Death 69.68 24.49 370 29282 698499 109861148
Rash maculo-papular 68.84 24.49 92 29560 74130 110485517
Gene mutation 68.59 24.49 28 29624 3401 110556246
Carbohydrate antigen 19-9 increased 68.44 24.49 18 29634 538 110559109
Gastrointestinal toxicity 66.77 24.49 40 29612 11108 110548539
Abdominal discomfort 65.52 24.49 13 29639 393845 110165802
Swelling 64.12 24.49 9 29643 351032 110208615
Musculoskeletal stiffness 62.46 24.49 3 29649 279819 110279828
Intestinal obstruction 62.12 24.49 74 29578 53153 110506494
Neoplasm progression 61.34 24.49 81 29571 64514 110495133
Pulmonary embolism 60.39 24.49 159 29493 214315 110345332
Anaemia 59.58 24.49 297 29355 546789 110012858
Dizziness 58.07 24.49 61 29591 698132 109861515
Pustule 57.98 24.49 25 29627 3479 110556168
Blepharitis 57.84 24.49 27 29625 4525 110555122
Product use in unapproved indication 57.49 24.49 24 29628 447353 110112294
Pain in extremity 56.65 24.49 30 29622 487088 110072559
Depilation 55.96 24.49 10 29642 41 110559606
Mucosal toxicity 55.19 24.49 16 29636 690 110558957
Ectropion 55.03 24.49 15 29637 515 110559132
Hepatic lesion 54.86 24.49 32 29620 8461 110551186
Asthma 54.86 24.49 3 29649 250288 110309359
Confusional state 54.30 24.49 29 29623 468651 110090996
Asthenia 53.79 24.49 342 29310 688657 109870990
Weight increased 53.14 24.49 23 29629 419621 110140026
Febrile neutropenia 52.21 24.49 195 29457 316572 110243075
Lower respiratory tract infection 50.08 24.49 4 29648 243102 110316545
Depression 49.67 24.49 12 29640 317323 110242324
Mucocutaneous rash 49.24 24.49 10 29642 90 110559557
Product dose omission issue 48.77 24.49 13 29639 321769 110237878
Colon cancer metastatic 48.58 24.49 20 29632 2481 110557166
Drug hypersensitivity 45.81 24.49 33 29619 454057 110105590
Pemphigus 45.72 24.49 3 29649 214567 110345080
Malignant neoplasm progression 45.69 24.49 126 29526 174441 110385206
Skin exfoliation 45.29 24.49 83 29569 87568 110472079
Insomnia 45.27 24.49 20 29632 360570 110199077
Therapeutic product effect decreased 45.23 24.49 6 29646 244310 110315337
Scab 44.15 24.49 33 29619 13203 110546444
Hepatic enzyme increased 43.21 24.49 16 29636 320876 110238771
Drug intolerance 43.05 24.49 28 29624 406484 110153163
Acne pustular 42.62 24.49 11 29641 305 110559342
Glossodynia 42.19 24.49 5 29647 221999 110337648
Device related infection 41.34 24.49 52 29600 39467 110520180
Wheezing 41.24 24.49 9 29643 255221 110304426
Cough 41.03 24.49 38 29614 461603 110098044
Metastasis 40.24 24.49 26 29626 8241 110551406
Anxiety 39.01 24.49 22 29630 345056 110214591
Sleep disorder 38.95 24.49 4 29648 198640 110361007
Hyperammonaemia 38.74 24.49 31 29621 13701 110545946
Diaphragmatic operation 38.56 24.49 7 29645 32 110559615
Thrombocytopenic purpura 38.53 24.49 18 29634 3021 110556626
Overdose 38.27 24.49 8 29644 233786 110325861
Somnolence 38.12 24.49 16 29636 297433 110262214
Product use issue 38.01 24.49 18 29634 311677 110247970
Transient aphasia 37.93 24.49 12 29640 697 110558950
Condition aggravated 37.50 24.49 89 29563 734747 109824900
Ascites 37.20 24.49 79 29573 92729 110466918
Dermatitis infected 37.17 24.49 11 29641 510 110559137
Mobility decreased 37.10 24.49 9 29643 237413 110322234
Treatment failure 37.02 24.49 14 29638 277220 110282427
Duodenal ulcer perforation 36.38 24.49 3 29649 177697 110381950
Pulmonary toxicity 35.68 24.49 33 29619 17713 110541934
Metastases to ovary 35.46 24.49 10 29642 390 110559257
Wound 34.52 24.49 10 29642 234427 110325220
Contusion 34.28 24.49 10 29642 233351 110326296
Cholangitis 34.06 24.49 31 29621 16304 110543343
Intravascular haemolysis 33.57 24.49 12 29640 1015 110558632
Ileal perforation 33.46 24.49 13 29639 1387 110558260
Papule 33.21 24.49 25 29627 10108 110549539
Adenocarcinoma 32.70 24.49 18 29634 4262 110555385
Rectal cancer metastatic 32.30 24.49 10 29642 541 110559106
Eczema impetiginous 32.13 24.49 6 29646 33 110559614
Metastases to pelvis 31.85 24.49 11 29641 841 110558806
Impaired healing 31.64 24.49 7 29645 196710 110362937
Epidermal naevus syndrome 30.98 24.49 5 29647 9 110559638
Xerophthalmia 30.67 24.49 11 29641 940 110558707
Eyelash changes 30.63 24.49 5 29647 10 110559637
Musculoskeletal pain 30.50 24.49 6 29646 183017 110376630
Urinoma 29.86 24.49 8 29644 257 110559390
Cardiac failure congestive 29.70 24.49 3 29649 150997 110408650
Bronchitis 28.71 24.49 4 29648 157028 110402619
Ill-defined disorder 28.67 24.49 4 29648 156849 110402798
Livedo reticularis 28.50 24.49 18 29634 5488 110554159
Subileus 28.31 24.49 19 29633 6418 110553229
Toxicity to various agents 27.98 24.49 54 29598 480501 110079146
Proctalgia 27.39 24.49 25 29627 13197 110546450
Anaphylactoid reaction 27.30 24.49 19 29633 6807 110552840
Keratitis 27.08 24.49 17 29635 5127 110554520
Dehydration 27.06 24.49 147 29505 279364 110280283
Hepatic failure 26.95 24.49 58 29594 68681 110490966
Cancer surgery 26.59 24.49 10 29642 977 110558670
Astringent therapy 26.55 24.49 5 29647 29 110559618
Gait inability 26.08 24.49 3 29649 136373 110423274
Perioral dermatitis 25.76 24.49 9 29643 712 110558935
Blood pressure increased 25.74 24.49 19 29633 258354 110301293
Metastases to central nervous system 25.43 24.49 31 29621 22786 110536861
Rash papular 25.22 24.49 34 29618 27605 110532042
Drug resistance 24.95 24.49 50 29602 56324 110503323
Enterocolitis 24.88 24.49 28 29624 18921 110540726
Tumour marker increased 24.84 24.49 16 29636 5044 110554603
Onycholysis 24.83 24.49 13 29639 2786 110556861

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FE02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
EGFR (Epidermal Growth Factor Receptor) inhibitors
FDA CS M0001357 Antibodies, Monoclonal
FDA MoA N0000020010 HER1 Antagonists
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
FDA EPC N0000175664 Epidermal Growth Factor Receptor Antagonist
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors 2 drugs
cetuximabnecitumumab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Secondary malignant neoplasm of colon indication 94260004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Epidermal growth factor receptor Kinase AGONIST Kd 10.30 IUPHAR DRUG LABEL

External reference:

IDSource
D05350 KEGG_DRUG
4025701 VUID
N0000179714 NUI
4025701 VANDF
CHEBI:749603 CHEBI
CHEMBL1201827 ChEMBL_ID
6883 IUPHAR_LIGAND_ID
DB01269 DRUGBANK_ID
263034 RXNORM
22205 MMSL
88497 MMSL
d05879 MMSL
011743 NDDF
423259008 SNOMEDCT_US
424401006 SNOMEDCT_US
C0879427 UMLSCUI
D000077544 MESH_DESCRIPTOR_UI
8499 INN_ID
6A901E312A UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-954 SOLUTION 100 mg INTRAVENOUS BLA 30 sections
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-956 SOLUTION 400 mg INTRAVENOUS BLA 30 sections